Also found in: Wikipedia.


Ciliary neurotrophic factor, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Rimonabant and Regeneron Pharmaceuticals' injectable Axokine were both briefly discussed, as both have recently completed last-stage testing, Axokine helped patients lose 3.5 kg more than placebo, said Dr.
One of those drugs, Axokine, recently received fast-track approval status from the Food and Drug Administration--a first for an obesity drug.
At least two are in phase III, placebo-controlled trials: Axokine, or ciliary neurotrophic factor (Regeneron Pharmaceuticals), and Rimonabant, a cannabinoid receptor agonist (Sanofi-Sythelabo).
Axokine, the drug now seen as having the best chance of reaching the market first, was found serendipitously Seeking to develop drugs for neurologic diseases, Regeneron identified ciliary neurotrophic factor as a possible agent and tested it in patients with amyotrophic lateral sclerosis.
Unlike Axokine, which is given daily by subcutaneous injection, Rimonabant is an oral agent.
Unlike Axokine, which is administered daily by subcutaneous injection, Rimonabant is an oral agent.